Results 241 to 250 of about 161,851 (302)

Combination mRNA Vaccine Adjuvanted with CpG Oligodeoxynucleotides Enhances Protection against Respiratory Virus Infection. [PDF]

ACS Nano
Cui L, Zhang S, Zeng Y, Zhang L, Lin M, Hong M, Chen H, Wang H, Xue W, Lan M, Liu H, Gao Y, Li H, Yin Y, Zhang H, Zheng Z, Chen Y, Chen J, Zhang Y, Gu Y, Li T, Li S, Xia N.   +22 more
europepmc   +1 more source

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations.

JAMA Pediatr
Attaianese F, Carreras G, Trapani S, Alberti I, Aricò M, Attanasi M, Bertolucci G, Bressan S, Caselli D, Casotto V, Cazzato S, Chiarelli F, Felici E, Frusciante A, Galeone MA, Garazzino S, Giannattasio A, Gitto E, Guerriero A, Guida F, Iudica G, Lanari M, Mandato C, Manzini A, Martelli G, Milani GP, Moriondo M, Notarangelo LD, Nunziata F, Pellegrino R, Peroni D, Piccotti E, Ponticiello E, Ricci S, Rulli I, Savoia F, Silvestro E, Sisto A, Soro F, Tonetto S, Zago A, Dani C, Azzari C, Indolfi G.   +43 more
europepmc   +1 more source

RSV Antibody Prophylaxis Needs for Extremely Preterm Infants in Their Second RSV Season.

JAMA Pediatr
Viñeta Paramo M, Watts A, Solimano A, Seaton C, Sadarangani M, Sbihi H, Lavoie PM.   +6 more
europepmc   +1 more source

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

New England Journal of Medicine, 2022
BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life.
Ron Dagan, Shabir A Madhi, William J Muller   +2 more
exaly   +2 more sources

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

New England Journal of Medicine, 2023
BACKGROUND Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain.
Shabir A Madhi, Julia R Glanternik, Fernando P Polack   +2 more
exaly   +2 more sources

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

New England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein, is under clinical investigation.
Edward E Walsh, Lauren Wilson
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults

New England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
Edward E Walsh, Fernando P Polack, Yasushi Fukushima   +2 more
exaly   +2 more sources

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

New England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease in older adults, but no licensed RSV vaccine currently exists.
Macaya Douoguih
exaly   +2 more sources